Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Completed · Phase 2

Conditions studied: Solid Tumors

In brief

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

Key facts

Study ID

NCT03477175

Run by

Eisai Inc.

People needed

40

Starts

2018-08-16

Expected to finish

2023-12-21

Last updated by the study team

2025-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• It is required for all participants currently participating in other lenvatinib studies to meet the following eligibility criteria.
• Provide signed written informed consent for the roll-over study
• Currently enrolled in an Eisai-sponsored lenvatinib clinical study and still receiving at least one of the study drugs from that protocol
• Currently deriving clinical benefit from at least one of the study drug(s) as determined by the investigator
• Must be able and willing to comply with the current roll-over protocol requirements
• Continued ability to swallow and retain orally administered study drug(s)
• Does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
• Women of childbearing potential and men with reproductive potential (if specified by the parent study) must be willing to continue to use highly effective methods of contraception as per local practices of standard of care during the period of the study
• Women of childbearing potential must have a negative serum pregnancy test at the time of transition to the study and before continuing study drug(s)

You may not qualify if…

• Permanent discontinuation of all study drug(s) in the parent study due to toxicity or disease progression and without clinical benefit
• Receiving any prohibited medication(s) as described in the parent study
• Any unresolved toxicity that meets the criteria for study drug(s) discontinuation or withdrawal criteria from the parent study at the time of transition to this study
• Uncontrolled diabetes, hypertension or other medical conditions at the time of transition to the roll-over study that may interfere with assessment of toxicity
• Pregnant or lactating female
• Any serious and/or unstable pre-existing medical condition, psychiatric disorder or other conditions at the time of transition to the roll-over study that could interfere with participant's safety in the opinion of the investigator

Where it is running

• Harbor UCLA Medical Center — Torrance, California, United States
• Northwestern University — Chicago, Illinois, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• The Alfred Hospital — Melbourne, Australia
• UZ Antwerpen — Edegem, Antwerpen, Belgium
• Cliniques Universitaires Saint-Luc — Brussels, Brussels Capital, Belgium
• Sun Yat-sen University, Cancer Center — Guangzhou, Guangdong, China
• Affiliated Hospital of Guilin Medical University — Guilin, Guangxi, China
• Harbin Medical University Cancer Hospital — Haerbin, Heilongjiang, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei, China
• Hunan Cancer Hospital — Changsha, Hunan, China
• Jiangsu Cancer Hospital — Nanjing, Jiangsu, China
• Nanjing First Hospital — Nanjing, Jiangsu, China
• The First Hospital of Jilin University — Changchun, Jilin, China
• No.10 People of Shanghai — Shanghai, Shanghai Municipality, China
• West China School of Medicine/West China Hospital, Sichuan University — Chengdu, Sichuan, China
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality, China
• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China
• Eisai trial site 2 — Essen, Germany
• Eisai trial site 1 — Würzburg, Germany
• Azienda Ospedaliero Universitaria Pisana — Pisa, Tuscany, Italy
• Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis — Amsterdam, North Holland, Netherlands
• Centrum Onkologii Instytut im.Marii Sklodowskiej Curie-Oddzial w Gliwicach — Gliwice, Poland
• Institutul National de Endocrinologie "C. I. Parhon" — Bucharest, Romania

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.